CTKB250117C2500
- 3.30
- 0.000.00%
Cytek Biosciences Newsroom
Morgan Stanley Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Maintains Target Price $9
Piper Sandler Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Cuts Target Price to $8.25
Morgan Stanley Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Maintains Target Price $9
Morgan Stanley Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Maintains Target Price $9
Cautious Hold on Cytek Biosciences Amid Recovery and Growth Opportunities
Cytek Biosciences Is Maintained at Overweight by Piper Sandler
Cytek Biosciences Analyst Ratings
Piper Sandler Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Raises Target Price to $8.5
TD Cowen Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Maintains Target Price $9
Piper Sandler Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Maintains Target Price $8
Piper Sandler Keeps Their Buy Rating on Cytek Biosciences (CTKB)
TD Cowen Initiates Cytek Biosciences(CTKB.US) With Buy Rating, Announces Target Price $9
Positive Outlook and Buy Rating for Cytek Biosciences Amid Strong International Performance and Strategic Expansion
Piper Sandler Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Maintains Target Price $8
Piper Sandler Reaffirms Their Buy Rating on Cytek Biosciences (CTKB)
Piper Sandler Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Cuts Target Price to $8
Cytek Biosciences Analyst Ratings
Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $8
Cytek Biosciences: Hold Rating Amidst Mixed Performance and Cautious U.S. Market Outlook
TD Cowen Maintains Cytek Biosciences(CTKB.US) With Buy Rating, Maintains Target Price $12